FibroBiologics, Inc. — Form 8-K Summary
Reporting date: October 7, 2026; the financing closed October 8, 2026. This current report describes a financing transaction, not quarterly or annual operating results.
Business context and financing
FibroBiologics entered into a securities purchase agreement with Peak One Opportunity Fund, L.P. for a private placement of a convertible debenture and restricted shares.
- Debenture principal: $1.2 million, sold for $1.02 million at a 15% original issue discount.
- Transaction fee: The Company paid Peak One $20,000 for transaction-related costs.
- Commitment shares: 125,000 restricted common shares issued to Peak One and its designee.
- Term and interest: Matures October 8, 2027; bears 0% annual interest unless an Event of Default occurs.
- Scheduled payments: $1.08 million on April 8, 2027; $60,000 on July 8, 2027; and $60,000, or the remaining balance if higher, at maturity.
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, operating margin, cash balance, or other liquidity figures. It does not provide comparable-period operating results. The financing supplies $1.02 million in purchase proceeds before the disclosed $20,000 fee and any other costs; the filing does not state net proceeds after all costs.
Material terms, risks, and outlook
- Conversion is permitted only following an Event of Default, at a fixed price of $0.78 per share. The maximum shares issuable through conversion is 1,671,094, subject to the Nasdaq Exchange Cap and other limits.
- The holder may accelerate the debt after an Event of Default at 120% of outstanding principal plus accrued and unpaid interest, and may raise the interest rate to the lesser of 18% annually or the legal maximum.
- At the holder’s discretion, 50% of the Company’s aggregate cash proceeds exceeding $1.5 million from specified sources must be used to repay amounts owed under the debenture.
- The Company may redeem the debenture at 100% of principal while no Event of Default is continuing. It also agreed, subject to limited exceptions, not to enter into a Variable Rate Transaction while the debenture is outstanding.
- Shares issued under the agreement and debenture are capped at 1,671,094 absent stockholder approval for additional issuance. A 4.99% beneficial-ownership limit also applies to the holder and its affiliates.
The filing gives no operating guidance or broader management outlook. Key risks include the large scheduled April 2027 payment, default-related interest and acceleration provisions, and potential share issuance subject to the stated caps and ownership limit.
Important facts for investors to verify
- Review Exhibits 10.1 and 10.2 for the full purchase agreement, debenture terms, definitions, and conditions.
- Confirm the Company’s cash position and ability to meet the April and July 2027 payments; this filing does not disclose liquidity data.
- Monitor any Event of Default, redemption, cash-proceeds repayment obligation, or changes to the outstanding balance.
- Verify the share-count and ownership limits, and whether stockholder approval would be required for any issuance above the Exchange Cap.